Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Trial of Deferiprone in Parkinson’s Disease

by Dušek, Petr , Post, Bart , Vilas, Dolores , Meissner, Wassilios G. , Simonin, Ophélie , Habert, Marie-Odile , Devos, David , Růžička, Evžen , Pavese, Nicola , Tricta, Fernando , Bloem, Bastiaan R. , Viard, Romain , Scherfler, Christoph , Fradette, Caroline , Berg, Daniela , Maetzler, Walter , Tranchant, Christine , Ayton, Scott , Lehericy, Stéphane , Deplanque, Dominique , Otto, Markus , Corvol, Jean-Christophe , Dodel, Richard , Moreau, Caroline , Garçon, Guillaume , Labreuche, Julien , Poewe, Werner , Thobois, Stéphane , Guyon Delannoy, Pauline , Lopes, Renaud , de Bie, Rob M.A. , Ouk, Thavarak , Coelho, Miguel V.S. , Leclercq, Céline , Compta, Yaroslau , Spino, Michael , Chupin, Marie , Eusebio, Alexandre , Januario, Cristina , Kuchcinski, Gregory , Defebvre, Luc , Bush, Ashley I. , Behnke, Stefanie , Worth, Paul , Seppi, Klaus , Nyholm, Dag , Kulisevsky, Jaime , Gago, Miguel , Mangin, Jean-François , Ory-Magne, Fabienne , Cabantchik, Ioav , Bordet, Régis , Ferreira, Joaquim , Carpentier, Jessica , Duhamel, Alain , Duce, James A. , Rolland, Anne-Sophie , Marques, Ana-Raquel , Devedjian, Jean-Christophe , Rascol, Olivier , Dexter, David T. , Pruvo, Jean-Pierre , Pig

in Administration, Oral / Aging / Aging General / Antiparkinson Agents - administration & dosage / Antiparkinson Agents - adverse effects / Antiparkinson Agents - pharmacology / Antiparkinson Agents - therapeutic use / Basal ganglia / Body weight / Brain - diagnostic imaging / Brain Chemistry / Central nervous system diseases / Clinical trials / Cognitive ability / Deferiprone - administration & dosage / Deferiprone - adverse effects / Deferiprone - pharmacology / Deferiprone - therapeutic use / Disease Progression / Dopamine / Dopamine Agents - administration & dosage / Dopamine Agents - adverse effects / Dopamine Agents - pharmacology / Dopamine Agents - therapeutic use / Dopamine receptors / Double-Blind Method / Double-blind studies / Genetics / Geriatrics / Hematology / Humans / Iron / Iron - analysis / Iron - metabolism / Iron Chelating Agents - administration & dosage / Iron Chelating Agents - adverse effects / Iron Chelating Agents - pharmacology / Iron Chelating Agents - therapeutic use / Levodopa / Levodopa - therapeutic use / Life Sciences / Magnetic resonance imaging / Metabolism / Movement disorders / Neurodegenerative diseases / Neuroimaging / Neurology / Neuroscience / Neurosurgery / Neutropenia / Neutropenia - chemically induced / Oncology / Oncology General / Parkinson Disease / Parkinson Disease - drug therapy / Parkinson Disease - metabolism / Parkinson Disease - physiopathology / Parkinson's disease / Placebos / Quality of life / Substantia nigra / Substantia Nigra - chemistry / Substantia Nigra - diagnostic imaging / Substantia Nigra - drug effects / Substantia Nigra - metabolism

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Trial of Deferiprone in Parkinson’s Disease

2022

Confirm

Do you wish to request the book?

Trial of Deferiprone in Parkinson’s Disease

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Trial of Deferiprone in Parkinson’s Disease

Dušek, Petr,

Post, Bart,

Vilas, Dolores,

Meissner, Wassilios G.,

Simonin, Ophélie,

Habert, Marie-Odile,

Devos, David,

Růžička, Evžen,

Pavese, Nicola,

Tricta, Fernando,

Bloem, Bastiaan R.,

Viard, Romain,

Scherfler, Christoph,

Fradette, Caroline,

Berg, Daniela,

Maetzler, Walter,

Tranchant, Christine,

Ayton, Scott,

Lehericy, Stéphane,

Deplanque, Dominique,

Otto, Markus,

Corvol, Jean-Christophe,

Dodel, Richard,

Moreau, Caroline,

Garçon, Guillaume,

Labreuche, Julien,

Poewe, Werner,

Thobois, Stéphane,

Guyon Delannoy, Pauline,

Lopes, Renaud,

de Bie, Rob M.A.,

Ouk, Thavarak,

Coelho, Miguel V.S.,

Leclercq, Céline,

Compta, Yaroslau,

Spino, Michael,

Chupin, Marie,

Eusebio, Alexandre,

Januario, Cristina,

Kuchcinski, Gregory,

Defebvre, Luc,

Bush, Ashley I.,

Behnke, Stefanie,

Worth, Paul,

Seppi, Klaus,

Nyholm, Dag,

Kulisevsky, Jaime,

Gago, Miguel,

Mangin, Jean-François,

Ory-Magne, Fabienne,

Cabantchik, Ioav,

Bordet, Régis,

Ferreira, Joaquim,

Carpentier, Jessica,

Duhamel, Alain,

Duce, James A.,

Rolland, Anne-Sophie,

Marques, Ana-Raquel,

Devedjian, Jean-Christophe,

Rascol, Olivier,

Dexter, David T.,

Pruvo, Jean-Pierre,

Pig

2022

Overview

Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Administration, Oral

/ Aging

/ Aging General

/ Antiparkinson Agents - administration & dosage

/ Antiparkinson Agents - adverse effects

/ Antiparkinson Agents - pharmacology

/ Antiparkinson Agents - therapeutic use